Skip to main content
. 2012 Mar 12;7(3):e32251. doi: 10.1371/journal.pone.0032251

Table 2. Prevalence of HPV 16/18 for women in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).

Prevalence of HPV 16/18 for women 10 years 20 years 50 years
Without vaccination 20.2% 20.2% 20.2%
Scenario 1 14.4% (−28.7%) 9.8% (−51.7%) 2.6% (−87.2%)
Scenario 2 13.7% (−32.2%) 8.31% (−58.9%) 0.85% (−95.8%)
Scenario 3 11.0% (−45.5%) 6.05% (−70.0%) 0.6% (−97.0%)
Scenario 4 10.1% (−50%) 4.69% (−76.8%) 0.09% (−99.6%)
Scenario 5 12.2% (−39.6%) 6.96% (−65.6%) 0.9% (−95.6%)

Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in HPV prevalence compared to the case without vaccination.